A novel event-free survival endpoint in locally advanced pancreatic cancer
The treatment paradigm for locally advanced pancreatic cancer (LAPC) is evolving rapidly. The development of neoadjuvant therapies composed of combination therapies and the evaluation of their impact on conversion to borderline resectable (BR) status, resection, and ultimately overall survival (OS)...
Guardado en:
Autores principales: | Pascal Hammel, Ewa Carrier, Mairead Carney, Mark Eisner, Thomas Fleming |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SAGE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/40c80974de284a6c9e33fe3074c7496e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Endpoint relations for baryons
por: Gudrun Hiller, et al.
Publicado: (2021) -
Postoperative pancreatic fistula affects recurrence-free survival of pancreatic cancer patients.
por: Sameer A Dhayat, et al.
Publicado: (2021) -
Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
por: G. C. Deng, et al.
Publicado: (2021) -
Identification of Circulating Biomarkers and Construction of a Prognostic Signature for Survival Prediction in Locally Advanced Pancreatic Cancer After Irreversible Electroporation
por: He C, et al.
Publicado: (2021) -
Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
por: Guang‐Li Zhu, et al.
Publicado: (2021)